Robert S. Hogg

Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals.

P. Harrigan, R. Hogg, J. Montaner, 2005, The Journal of infectious diseases.

Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies

Stephen R Cole, Jonathan A C Sterne, Ross Harris, 2009, The Lancet.

Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response

P. Harrigan, R. Hogg, J. Montaner, 2003, AIDS.

The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs.

B. Yip, R. Hogg, J. Montaner, 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Emergence of Drug Resistance Is Associated with an Increased Risk of Death among Patients First Starting HAART

P. Harrigan, B. Yip, R. Hogg, 2006, PLoS medicine.

Mitochondrial:nuclear DNA ratios in peripheral blood cells from human immunodeficiency virus (HIV)-infected patients who received selected HIV antiretroviral drug regimens.

P. Harrigan, B. Yip, R. Hogg, 2003, The Journal of infectious diseases.

Models of survival in HIV infection and their use in the quantification of treatment benefits.

R. Hogg, J. Montaner, M. Schechter, 1998, American journal of epidemiology.

Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS

A. Levy, R. Hogg, J. Montaner, 2005, Lipids in Health and Disease.

The end of the line: has rapid transit contributed to the spatial diffusion of HIV in one of Canada's largest metropolitan areas?

R. Hogg, J. Montaner, M. Schechter, 2000, Social science & medicine.